Carderock Capital Management Inc. Decreases Stake in Danaher Co. (NYSE:DHR)

Carderock Capital Management Inc. trimmed its position in Danaher Co. (NYSE:DHR) by 7.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 19,683 shares of the conglomerate’s stock after selling 1,595 shares during the period. Carderock Capital Management Inc.’s holdings in Danaher were worth $4,518,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Decker Retirement Planning Inc. purchased a new position in Danaher in the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC purchased a new stake in Danaher in the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new position in Danaher in the third quarter valued at $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Royal Bank of Canada cut their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Guggenheim initiated coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. Finally, Scotiabank assumed coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Stock Down 1.4 %

Danaher stock opened at $238.41 on Friday. The stock’s 50 day moving average price is $234.99 and its 200 day moving average price is $253.37. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The company has a market cap of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the firm earned $2.02 EPS. The business’s revenue was up 3.1% on a year-over-year basis. On average, sell-side analysts predict that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.